Ignite Creation Date:
2025-12-25 @ 1:20 AM
Ignite Modification Date:
2026-01-12 @ 10:06 PM
Study NCT ID:
NCT06594393
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-08-28
First Post:
2024-08-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D004820', 'term': 'Epidermolysis Bullosa'}], 'ancestors': [{'id': 'D012868', 'term': 'Skin Abnormalities'}, {'id': 'D000013', 'term': 'Congenital Abnormalities'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012872', 'term': 'Skin Diseases, Vesiculobullous'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Intra-subject control'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 26}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-08-27', 'studyFirstSubmitDate': '2024-08-29', 'studyFirstSubmitQcDate': '2024-09-10', 'lastUpdatePostDateStruct': {'date': '2025-08-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-09-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Open wound area', 'timeFrame': '56 days'}], 'secondaryOutcomes': [{'measure': 'Frequency, intensity, and seriousness of Adverse Events in all treated patients until end of treatment', 'timeFrame': '56 days'}, {'measure': 'Change in procedural pain using the Wong Baker FACES® Pain Rating Scale (0 min -10 max)', 'timeFrame': '56 days', 'description': 'Wong Baker FACES pain rating scale uses 6 graphically or cartoon-depicted faces with varying facial expressions that represent no pain (no hurt) (Face 0) to worst pain/hurt that can be imagined (Face 10).'}, {'measure': 'Change from baseline in clinical impression of overall treatment area', 'timeFrame': '56 days'}, {'measure': 'TCP-25 plasma concentrations', 'timeFrame': '56 days'}, {'measure': 'Number of participants with treatment-related local tolerability assessment at the area of IMP application assessed on a 4-point scale', 'timeFrame': '56 days'}, {'measure': 'Clinically significant changes from baseline in blood pressure until end of treatment', 'timeFrame': '56 days'}, {'measure': 'Number of patients with clinically significant changes from baseline in pulse rate until end of treatment', 'timeFrame': '56 days'}, {'measure': 'Number of patients with clinically significant changes from baseline in physical examination findings until end of treatment', 'timeFrame': '56 days'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Epidermolysis Bullosa (EB)']}, 'referencesModule': {'references': [{'pmid': '36813496', 'type': 'BACKGROUND', 'citation': 'Lundgren S, Wallblom K, Fisher J, Erdmann S, Schmidtchen A, Saleh K. Study protocol for a phase 1, randomised, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of ascending topical doses of TCP-25 applied to epidermal suction blister wounds in healthy male and female volunteers. BMJ Open. 2023 Feb 22;13(2):e064866. doi: 10.1136/bmjopen-2022-064866.'}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, pairs of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.', 'detailedDescription': 'The study will include a Screening Period, a Treatment Period (Days 1 to 56, with study visits conducted every 2 weeks, including the baseline \\[Day 1\\], Day 14, Day 28, Day 42, and Day 56 visits) and a Safety Follow-up conducted via a telephone/video call at approximately 14 days after the last dose of the IMP. Patients will undergo efficacy, safety, tolerability, and PK assessments at scheduled visits. For evaluation of the primary efficacy endpoint, a trained clinician will take the images of the index wounds at all scheduled visits from baseline through Day 56 (Visit 6) using 3D digital photography and software for wound measurement.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '4 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male or female patients with documented diagnosis of DEB or JEB, confirmed by genetic testing and/or by a skin biopsy with immunofluorescence mapping.\n* Patients ≥4 years old. Note: Initially, patients ≥12 years will be enrolled. Enrollment will be open to 4 to 11 year old pediatric patients (both inclusive), after a DMC reviews and provides a positive opinion regarding the safety and tolerability of the IMP in at least 3 patients 12 to 18 years old who have completed at least 4 weeks of IMP use.\n\nExclusion Criteria:\n\n* The patient has any subtype of EB other than DEB or JEB.\n* The patient is currently being treated or planned to be treated with systemic antibiotics.\n\nNote: Use of preventive and/or anti-inflammatory antibiotic treatment, including doxycycline, on an established treatment regimen (stable dose for ≥6 weeks before the Baseline Visit) is permitted. Use of topical antibiotics on the index wounds within 7 days before the Baseline Visit is prohibited.\n\n• Use of systemic corticosteroids \\>0.2 mg/kg prednisone dose equivalent per day within 30 days or use of topical corticosteroids on index wounds within 7 days before the Screening Visit.\n\nNote: Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted.\n\n• The patient has a history of or current malignancy over the index wound, eg, basal cell carcinoma or squamous cell carcinoma.'}, 'identificationModule': {'nctId': 'NCT06594393', 'acronym': 'STEP', 'briefTitle': 'A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study', 'organization': {'class': 'INDUSTRY', 'fullName': 'Xinnate AB'}, 'officialTitle': 'A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa', 'orgStudyIdInfo': {'id': 'TCP25-002'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TCP-25', 'description': 'Topical gel', 'interventionNames': ['Drug: TCP-25 gel']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Vehicle', 'description': 'Placebo gel', 'interventionNames': ['Drug: Vehicle (placebo)']}], 'interventions': [{'name': 'TCP-25 gel', 'type': 'DRUG', 'description': 'Topical gel', 'armGroupLabels': ['TCP-25']}, {'name': 'Vehicle (placebo)', 'type': 'DRUG', 'description': 'Placebo gel', 'armGroupLabels': ['Vehicle']}]}, 'contactsLocationsModule': {'locations': [{'zip': '23735', 'city': 'Lund', 'state': 'Skåne County', 'country': 'Sweden', 'contacts': [{'name': 'Principal investigator', 'role': 'CONTACT', 'email': 'info@regionskane.se', 'phone': '46 46 17 100'}], 'facility': 'University hospital', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}], 'centralContacts': [{'name': 'Head of Clinical Development', 'role': 'CONTACT', 'email': 'info@xinnate.com', 'phone': '46462756000'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Xinnate AB', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}